Table 3. Belotecan: second-line studies in patients with small cell lung cancer.
| Author [year] | Treatment-free interval | Scheme | Number of patients | ORR (%) | PFS (months) | Median survival (months) | Survival (%) |
|---|---|---|---|---|---|---|---|
| Rhee et al. (82) [2011] | All patients on relapse (platinum sensitivity was not defined) | B | 25 | 24 | PFS: 2.2 | 9.9 | 1 year: 38.3 |
| Jeong et al. (83) [2010] | ≥3 months | B | 27 | 22 | PFS: 4.7 | 13.1 | NR |
| Kim et al. (84) [2012] | All patients on relapse (platinum sensitivity was not defined) | B | 50 (30 refractory, 20 sensitive) | 14 (10 refractory, 20 sensitive) | PFS: 1.6; refractory: 1.5; sensitive: 2.8 | 4.5; refractory: 4.0; sensitive: 6.5 | NR |
B, belotecan; ORR, overall response rate; PFS, progression-free survival; NR, non-reported.